These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28105902)

  • 21. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer.
    Lantis JC; Boone D; Gendics C; Todd G
    Adv Skin Wound Care; 2009 Apr; 22(4):167-71. PubMed ID: 19325276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetic foot ulcer management in clinical practice in the UK: costs and outcomes.
    Guest JF; Fuller GW; Vowden P
    Int Wound J; 2018 Feb; 15(1):43-52. PubMed ID: 29243399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of Novel Macrophage-Regulating Treatment for Wound Healing in Patients With Diabetic Foot Ulcers From the Taiwan Health Care Sector Perspective.
    Su HY; Yang CY; Ou HT; Chen SG; Chen JC; Ho HJ; Kuo S
    JAMA Netw Open; 2023 Jan; 6(1):e2250639. PubMed ID: 36633847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A model to estimate cost-savings in diabetic foot ulcer prevention efforts.
    Barshes NR; Saedi S; Wrobel J; Kougias P; Kundakcioglu OE; Armstrong DG
    J Diabetes Complications; 2017 Apr; 31(4):700-707. PubMed ID: 28153676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers.
    Zelen CM; Orgill DP; Serena T; Galiano R; Carter MJ; DiDomenico LA; Keller J; Kaufman J; Li WW
    Int Wound J; 2017 Apr; 14(2):307-315. PubMed ID: 27073000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and economic assessment of diabetic foot ulcer debridement with collagenase: results of a randomized controlled study.
    Tallis A; Motley TA; Wunderlich RP; Dickerson JE; Waycaster C; Slade HB;
    Clin Ther; 2013 Nov; 35(11):1805-20. PubMed ID: 24145042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.
    Langer A; Rogowski W
    BMC Health Serv Res; 2009 Jul; 9():115. PubMed ID: 19591680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Burden of diabetic foot ulcers for medicare and private insurers.
    Rice JB; Desai U; Cummings AK; Birnbaum HG; Skornicki M; Parsons NB
    Diabetes Care; 2014; 37(3):651-8. PubMed ID: 24186882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of Lower Extremity Nerve Decompression Surgery in the Prevention of Ulcers and Amputations: A Markov Analysis.
    Rinkel WD; Franks B; Birnie E; Castro Cabezas M; Coert JH
    Plast Reconstr Surg; 2021 Nov; 148(5):1135-1145. PubMed ID: 34705790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries.
    Ghatnekar O; Willis M; Persson U
    J Wound Care; 2002 Feb; 11(2):70-4. PubMed ID: 11901743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of clostridial collagenase ointment on wound closure in patients with diabetic foot ulcers: economic analysis of results from a multicenter, randomized, open-label trial.
    Motley TA; Gilligan AM; Lange DL; Waycaster CR; Dickerson JE
    J Foot Ankle Res; 2015; 8():7. PubMed ID: 25767565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health economics for treatment of diabetic foot ulcers: a cost-effectiveness analysis of eight skin substitutes.
    Samsell B; McLean J; Cazzell S; Dorsch K; Moyer PM; Moore M
    J Wound Care; 2019 Sep; 28(Sup9):S14-S26. PubMed ID: 31509489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers.
    Carls GS; Gibson TB; Driver VR; Wrobel JS; Garoufalis MG; Defrancis RR; Wang S; Bagalman JE; Christina JR
    J Am Podiatr Med Assoc; 2011; 101(2):93-115. PubMed ID: 21406693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Geographic variation in Medicare spending and mortality for diabetic patients with foot ulcers and amputations.
    Sargen MR; Hoffstad O; Margolis DJ
    J Diabetes Complications; 2013; 27(2):128-33. PubMed ID: 23062327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The costs of diabetic foot: the economic case for the limb salvage team.
    Driver VR; Fabbi M; Lavery LA; Gibbons G
    J Am Podiatr Med Assoc; 2010; 100(5):335-41. PubMed ID: 20847346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer HealingChanges in Wound Surface Area.
    Waycaster CR; Gilligan AM; Motley TA
    J Am Podiatr Med Assoc; 2016 Jul; 106(4):273-82. PubMed ID: 27049838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cost analysis of diabetic lower-extremity ulcers.
    Harrington C; Zagari MJ; Corea J; Klitenic J
    Diabetes Care; 2000 Sep; 23(9):1333-8. PubMed ID: 10977028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru.
    Cárdenas MK; Mirelman AJ; Galvin CJ; Lazo-Porras M; Pinto M; Miranda JJ; Gilman RH
    BMC Health Serv Res; 2015 Oct; 15():483. PubMed ID: 26503154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dehydrated human amnion and chorion allograft versus standard of care alone in treatment of Wagner 1 diabetic foot ulcers: a trial-based health economics study.
    Carter MJ
    J Med Econ; 2020 Nov; 23(11):1273-1283. PubMed ID: 32729342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of characteristics and healing course of diabetic foot ulcers by etiological classification: neuropathic, ischemic, and neuro-ischemic type.
    Yotsu RR; Pham NM; Oe M; Nagase T; Sanada H; Hara H; Fukuda S; Fujitani J; Yamamoto-Honda R; Kajio H; Noda M; Tamaki T
    J Diabetes Complications; 2014; 28(4):528-35. PubMed ID: 24846054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.